Gate Square “Creator Certification Incentive Program” — Recruiting Outstanding Creators!
Join now, share quality content, and compete for over $10,000 in monthly rewards.
How to Apply:
1️⃣ Open the App → Tap [Square] at the bottom → Click your [avatar] in the top right.
2️⃣ Tap [Get Certified], submit your application, and wait for approval.
Apply Now: https://www.gate.com/questionnaire/7159
Token rewards, exclusive Gate merch, and traffic exposure await you!
Details: https://www.gate.com/announcements/article/47889
Nutriband Completes Strategic Divestment: $5 Million Deal Transfers Pocono Pharma Stake To EarthVision Bio
Nutriband Inc. (NTRB) has finalized a major portfolio transaction, transferring a 90% ownership stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio in exchange for $5 million. The move represents a strategic pivot focused on prioritizing core product development.
The Acquirer’s Track Record
EarthVision Bio brings substantial credentials to the transaction. The company specializes in developing sustainable alternatives to conventional materials, with backing from notable figures including Dr. Gordon Moore, Intel’s founder, and Dr. Hans Franke, former board chairman of Chevron Europe. Their mission centers on replacing plastic, molded fiber, wood, and paper products with environmentally-conscious substitutes.
Capital Allocation and Shareholder Position
Following the transaction, Nutriband shareholders will maintain a 10% stake in EarthVision Bio, preserving ongoing exposure to the acquirer’s growth trajectory. The $5 million proceeds from this divestment will be redirected toward accelerating development of AVERSA Fentanyl, the company’s flagship pharmaceutical asset.
AVERSA Fentanyl: Positioning For Market Dominance
AVERSA Fentanyl represents Nutriband’s concentrated bet on the abuse-deterrent opioid space. The transdermal patch technology is engineered to resist tampering and misuse while minimizing accidental exposure risks—positioning it as a potential first-to-market solution with these integrated safeguards. Market projections suggest the product could capture $80 million to $200 million in annual US revenues at peak adoption, underscoring the strategic importance of this capital reallocation.
The transaction underscores how biotech companies are increasingly streamlining portfolios to concentrate resources on high-potential pipeline assets with substantial commercial runway.
Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.